Marksans Pharma Q1 Results: Shares jump 11% after profit nearly triples, margin expands

Marksans Managing Director Mark Saldanha said Q1FY27 marked a strong start to the financial year, with quarterly EBITDA reaching a record ₹213 crore and PAT at around ₹159 crore. The company’s UK and Europe formulation business reported its highest-ever quarterly revenue of ₹356 crore, up 74.7% year-on-year.

Leave a Reply

Your email address will not be published. Required fields are marked *